SG10201609145PA - Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions - Google Patents

Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Info

Publication number
SG10201609145PA
SG10201609145PA SG10201609145PA SG10201609145PA SG10201609145PA SG 10201609145P A SG10201609145P A SG 10201609145PA SG 10201609145P A SG10201609145P A SG 10201609145PA SG 10201609145P A SG10201609145P A SG 10201609145PA SG 10201609145P A SG10201609145P A SG 10201609145PA
Authority
SG
Singapore
Prior art keywords
imidazol
ylmethyl
tetrahydro
quinoline
conditions
Prior art date
Application number
SG10201609145PA
Other languages
English (en)
Inventor
Mohammed I Dibas
Edward C Hsia
John E Donello
Daniel W Gil
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201609145P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of SG10201609145PA publication Critical patent/SG10201609145PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
SG10201609145PA 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions SG10201609145PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161558104P 2011-11-10 2011-11-10

Publications (1)

Publication Number Publication Date
SG10201609145PA true SG10201609145PA (en) 2016-12-29

Family

ID=47178364

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201609145PA SG10201609145PA (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
SG11201402246RA SG11201402246RA (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
SG10201809506TA SG10201809506TA (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG11201402246RA SG11201402246RA (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
SG10201809506TA SG10201809506TA (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Country Status (21)

Country Link
US (4) US20130123303A1 (zh)
EP (3) EP3184110B1 (zh)
JP (2) JP6359456B2 (zh)
KR (1) KR102004563B1 (zh)
CN (1) CN104136029A (zh)
AR (1) AR088845A1 (zh)
AU (2) AU2012335803B2 (zh)
BR (1) BR112014011336A2 (zh)
CA (1) CA2855005C (zh)
CL (1) CL2014001242A1 (zh)
DK (1) DK2776034T3 (zh)
ES (1) ES2635421T3 (zh)
IL (3) IL232483B (zh)
MX (1) MX350662B (zh)
MY (1) MY182553A (zh)
RU (2) RU2630978C2 (zh)
SG (3) SG10201609145PA (zh)
TW (3) TWI580424B (zh)
UA (1) UA109359C2 (zh)
WO (1) WO2013070861A1 (zh)
ZA (1) ZA201403396B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
US20140329874A1 (en) * 2013-05-06 2014-11-06 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
FR3061434B1 (fr) * 2017-01-04 2019-07-12 Pierre Fabre Dermo-Cosmetique Composition cosmetique comprenant une association d'huile de pongamia et de pentylene glycol 4-t-butylcyclohexanol pour lutter contre la rosacee
RU2727695C1 (ru) * 2020-02-13 2020-07-22 Мурад Умарович Магомедов Способ комплексного лечения ринофимы

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1075265T3 (da) * 1998-05-08 2006-06-26 Univ Miami Anvendelse af tetracycliner til behandling af sygdom i de Meibomske kirtler
WO2004073708A1 (en) * 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
US20010049369A1 (en) * 2000-02-10 2001-12-06 Jablonski Monica M. Brimonidine compositions and methods for retinal degeneration
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US20040146539A1 (en) * 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
AU2004293105B2 (en) * 2003-11-20 2010-09-09 Othera Holding, Inc. Amelioration of macular degeneration and other ophthalmic diseases
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
MXPA06013649A (es) * 2004-05-25 2007-07-09 Sansrosa Pharmaceutical Dev In Compuestos, formulaciones, y metodos para tratar o prevenir desordenes inflamatorios de la piel.
US20070203144A1 (en) * 2006-01-17 2007-08-30 Allergan, Inc. Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
US7323477B2 (en) * 2006-02-02 2008-01-29 Allergan, Inc. 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
RU2321399C1 (ru) * 2006-06-01 2008-04-10 Федеральное государственное учреждение "Нижегородский научно-исследовательский кожно-венерологический институт Федерального агентства по здравоохранению и социальному развитию" Способ лечения больных розацеа
WO2008124151A2 (en) * 2007-04-09 2008-10-16 Avicena Group, Inc. Use of creatine compounds for the treatment of eye disorders
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
US8455548B2 (en) * 2007-10-18 2013-06-04 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
US20100028266A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development. Inc. Composition and methods for treating allergic response
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
FR2942138A1 (fr) 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
WO2011053487A1 (en) * 2009-10-26 2011-05-05 Galderma Pharma S.A. Methods of treating or preventing acute erythema
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
AU2011231543B2 (en) * 2010-03-26 2015-01-15 Galderma Research & Development Improved methods and compositions for safe and effective treatment of erythema
BR112012024476A2 (pt) * 2010-03-26 2017-03-01 Galderma Res & Dev método para fornecer um tratamento seguro e efetivo da telangiectasia e método de produzir um produto embalado
KR20130128375A (ko) * 2010-08-06 2013-11-26 갈데르마 리서치 & 디벨로프먼트 피부 질환을 치료 또는 예방하기 위한 화합물들의 배합물

Also Published As

Publication number Publication date
TWI580424B (zh) 2017-05-01
US20160051534A1 (en) 2016-02-25
CA2855005A1 (en) 2013-05-16
AU2012335803B2 (en) 2016-05-26
IL261269A (en) 2018-10-31
IL232483A0 (en) 2014-06-30
US20150231128A1 (en) 2015-08-20
IL232483B (en) 2018-10-31
TW201713338A (zh) 2017-04-16
ZA201403396B (en) 2015-07-29
JP6526737B2 (ja) 2019-06-05
RU2667645C1 (ru) 2018-09-21
TW202014189A (zh) 2020-04-16
ES2635421T3 (es) 2017-10-03
MX350662B (es) 2017-09-13
RU2014122758A (ru) 2015-12-20
CA2855005C (en) 2016-11-22
EP2776034B1 (en) 2017-03-22
AR088845A1 (es) 2014-07-10
AU2012335803A1 (en) 2014-05-29
JP2014533271A (ja) 2014-12-11
BR112014011336A2 (pt) 2017-05-02
IL268757A (en) 2019-10-31
CN104136029A (zh) 2014-11-05
JP2017149767A (ja) 2017-08-31
CL2014001242A1 (es) 2014-11-14
SG11201402246RA (en) 2014-06-27
NZ624771A (en) 2016-11-25
KR102004563B1 (ko) 2019-07-26
US20130123303A1 (en) 2013-05-16
EP3763370A1 (en) 2021-01-13
JP6359456B2 (ja) 2018-07-18
EP3184110A1 (en) 2017-06-28
EP2776034A1 (en) 2014-09-17
MY182553A (en) 2021-01-25
AU2016216627A1 (en) 2016-09-08
DK2776034T3 (en) 2017-07-10
US9308201B2 (en) 2016-04-12
TW201328694A (zh) 2013-07-16
AU2016216627B2 (en) 2017-10-19
WO2013070861A1 (en) 2013-05-16
US20170095466A1 (en) 2017-04-06
TWI708604B (zh) 2020-11-01
KR20140107237A (ko) 2014-09-04
UA109359C2 (xx) 2015-08-10
SG10201809506TA (en) 2018-11-29
MX2014005640A (es) 2014-09-22
EP3184110B1 (en) 2020-10-07
RU2630978C2 (ru) 2017-09-15

Similar Documents

Publication Publication Date Title
IL236221A (en) History of theophyridone and pharmacological preparations containing them for the treatment of diseases
HK1199099A1 (zh) 用於治療和診斷癌症的方法和組合物
EP2621499A4 (en) METHODS OF TREATING ALLERGIC DISEASES
RS56720B1 (sr) Jedinjenja i kompozicije za lečenje parazitskih oboljenja
PL2643004T3 (pl) Kompozycja oligosacharydów do leczenia chorób skóry
MX349004B (es) Nuevos compuestos.
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
IL268757A (en) Pharmaceutical preparations containing 7-(H1-imidazol-4-ylmethyl)-8,7,6,5-tetrahydroquinoline for the treatment of skin diseases and conditions
EP2723924A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CANCER
EP2654745A4 (en) COMPOSITION FOR TREATING SKIN CONDITIONS OF THE SKIN
HK1198909A1 (zh) 用於治療肝臟疾病和障礙的組合物和方法
EP2691529A4 (en) METHOD AND COMPOSITIONS FOR TREATING BRAIN DISEASES
PT2539352T (pt) Composições e métodos para tratar doenças cardíacas
HK1197235A1 (zh) 二氫吡唑、其藥物組合物及其治療生育障礙的用途
HK1210163A1 (zh) 用於治療或預防肺炎病毒感染和相關疾病的組合物和方法
EP2709632A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES
PL392436A1 (pl) Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
EP2785335B8 (en) Methods and pharmaceutical compositions for the treatment of darier disease
EP2872166A4 (en) COMPOSITIONS AND METHODS OF DETECTING, TREATING AND PREVENTING ILLNESSES AND DISORDERS
IL225755A0 (en) Amido-6 derivatives of epoxymorphinans-a5, 4 for the treatment of pain
PL395469A1 (pl) Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
PT2456445E (pt) Agente para o tratamento de condições da pele
ZA201304121B (en) Arlysulfonamide derivatives for the prevention or treatment of specific ophthalmologic disorders
HK1157189A1 (en) Pharmaceutical composition for the treatment of tumor diseases